Retinal vein occlusion is a medical condition where there is a blockage in the retinal veins. This blocks the flow of blood in the retina, which can damage the nerve cells of the eye and result in loss of vision. Retinal vein occlusion can occur as a result of a clot in a vein, especially if the veins of the eye are very narrow. The disease is likely to affect people who are already suffering from hypertension, diabetes mellitus, or hyperlipidaemia.
Retinal vein occlusion is one of the most common causes of blindness after diabetic retinopathy. It is also one of the most common vascular disorders of the eye. Retinal vein occlusion can be broadly classified into two types, central retinal vein occlusion and branch retinal vein occlusion, with the latter being more frequent. Central retinal vein occlusion can be divided into two further subtypes, ischemic central retinal vein occlusion and non-ischemic central retinal vein occlusion.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Market Research Methodology
06. Market Landscape
07. Pipeline Portfolio
08. Rate of Incidence and Prevalence
09. Market Segmentation by Type of Therapy
10. Market Segmentation by Route of Administration
11. Market Segmentation by Dosage Forms
12. Geographical Segmentation
13. Buying Criteria
14. Market Growth Drivers
15. Drivers and their Impact
16. Market Challenges
17. Impact of Drivers and Challenges
18. Market Trends
19. Trends and their Impact
20. Vendor Landscape
21. Key Vendor Analysis
22. Other Reports in this Series
- Bayer AG
- F. Hoffmann-La Roche Ltd.
- Novartis AG
- Regeneron Pharmaceuticals Inc.
- Alimera Sciences
- Bristol-Myers Squibb
- Santen Pharmaceutical Co.
- Valeant Pharmaceuticals International
For more information visit http://www.researchandmarkets.com/research/s4zkfc/global_retinal
Media Contact: Laura Wood, +353-1-481-1716, email@example.com
SOURCE Research and Markets